A comparison of the efficacy and safety of loxaglate and lobitridol in renal angioplasty

Purpose: To compare ioxaglate and iobitridol for percutaneous transluminal renal angioplasty (PTRA) as regards thromboembolic complications, the quali ty of diagnosis, and renal and general safety. Methods: One hundred and eighty-nine patients were prospectively studied, 9 8 of whom received ioxaglate, and 91, iobitridol. Twenty-two were secondari ly excluded from the evaluation of thromboembolic complications as they did not undergo PTRA. Results: Two hundred and two PTRAs were performed. The total volumes of con trast medium administered and the procedure durations were the same for eac h patient. In the ioxaglate group, four dissections (3 stents), one occlusi ve dissection, and two spasms occurred; in the iobitridol group, there were three dissections (all stented), one occlusive dissection (stented), and t wo spasms. The final angiograms showed four renal infarctions with ioxaglat e (2 of which were in patients who were not anticoagulated), two with iobit ridol. No significant difference was seen in the incidence of thromboemboli c complications when the PTRA was performed after anticoagulation (n = 150; 3.9% vs 4%, p = 0.78); in the whole population, thromboembolic com plicati ons were more frequent in the ioxaglate group but the difference was not si gnificant (5.7% vs 3.7%, p = 0.74). The quality of the diagnosis and the ge neral and renal safety were the same in the two groups. Conclusion: Regarding the clotting phenomenon, we recorded as many thromboe mbolic complications with ioxaglate as with iobitridol.